Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype
Clinical trial NCT05951205 · WITHDRAWN
Trial details
- NCT number
- NCT05951205
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2027-07-31
- Primary completion
- 2033-12-31
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.